Skip to main content
Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
11.23
+0.03 (0.27%)
At close: Jun 6, 2025, 4:00 PM
11.50
+0.27 (2.43%)
After-hours: Jun 6, 2025, 7:37 PM EDT

Roivant Sciences Revenue

In the fiscal year ending March 31, 2025, Roivant Sciences had annual revenue of $29.05M, down -11.19%. Roivant Sciences had revenue of $7.57M in the quarter ending March 31, 2025, a decrease of -16.08%.

Revenue (ttm)
$29.05M
Revenue Growth
-11.19%
P/S Ratio
280.39
Revenue / Employee
$31,997
Employees
908
Market Cap
7.63B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 202529.05M-3.66M-11.19%
Mar 31, 202432.71M1.18M3.75%
Mar 31, 202331.53M-23.76M-42.97%
Mar 31, 202255.29M31.49M132.34%
Mar 31, 202123.80M-43.89M-64.85%
Mar 31, 2020 Pro Pro Pro
Mar 31, 2019 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 410.06B
Johnson & Johnson 89.33B
Merck & Co. 63.92B
AbbVie 57.37B
AstraZeneca 54.98B
Novartis AG 53.22B
Eli Lilly and Company 49.00B
Novo Nordisk 43.92B
Revenue Rankings

ROIV News

More News